直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Heightened Burden on Patentee Amending Claims at PTAB

January 31, 2014

Over the last year, the PTAB has issued a number of orders providing guidance on the procedures for amending claims in IPRs, PGRs, and CBMs. In its latest final written decision, Idle Free Systems, Inc. v. Bergstorm Inc., IPR2012-00027, Paper 77 (January 7, 2014), the Board discussed at length the burden placed on a patentee seeking to amend its challenged claims.

First, the Board distinguished post-grant proceedings from pre-grant examination and post-grant reexamination. Unlike those examination contexts, proposed amendments or substitute claims are not entered and then subjected to a thorough examination. Rather, during post-grant proceedings, the proposed amended or substitute claims are “added directly to the patent, without examination, if the patent owner’s motion to amend claims is granted.” To that end, the Board clarified that the burden is on the patentee to demonstrate that the amended or substitute claims are patentable over the prior art in general, not just the art of record.

While a patentee is not assumed to be aware of every item of prior art, the PTAB stated that a patentee “can, and is expected to set forth what it does know about the level of ordinary skill in the art, and what was previously known, regarding each feature it relies and focuses on for establishing patentability of its proposed substitute claims.” Where a patentee is unaware of the teachings of the newly added feature in the art, the patentee is expected to make such a statement to the Board. Otherwise, the Board requires that the patentee explain what was previously known and why it would not have been applicable to render the amended or substitute claims obvious to one with ordinary skill in the art.

These requirements place a heightened burden on patentees. It is not enough for a patentee merely to distinguish its proposed amended claims or substitute claims over the prior art of record. Instead, a motion to amend should include a discussion of the art that was known, a discussion of the level of ordinary skill in the art, and the reasons why the amended or substitute claims are patentable over the known art.

Tags

claim amendments

Copyright © 2014 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP